» Medarex Announces Allowance Of Investigational New Drug Application For Wholly-Owned Fully Human Anti-PD-L1 Antibody, MDX-1105
Medarex, Inc. (Nasdaq: MEDX) announced the allowance of an investigational new drug application (IND) filed with the U.S. Food & Drug Administration (FDA) for MDX-1105, for the treatment of patients…